Credit: Stock
What if the cure for a life-threatening heart condition wasn’t a drug or surgery, but a supplement you could find on a store shelf?
Japanese researchers have uncovered that tricaprin, a dietary supplement, triggered a dramatic reversal of heart disease symptoms in two patients with a rare, treatment-resistant condition. After years of chest pain and failed therapies, the patients experienced relief and even regression of artery-clogging fat deposits. The key wasn’t lowering cholesterol, but breaking down triglycerides inside heart cells—a novel and potentially groundbreaking approach to cardiac care.
What if the cure for a life-threatening heart condition wasn’t a drug or surgery, but a supplement you could find on a store shelf?
Japanese researchers have uncovered that tricaprin, a dietary supplement, triggered a dramatic reversal of heart disease symptoms in two patients with a rare, treatment-resistant condition. After years of chest pain and failed therapies, the patients experienced relief and even regression of artery-clogging fat deposits. The key wasn’t lowering cholesterol, but breaking down triglycerides inside heart cells—a novel and potentially groundbreaking approach to cardiac care.
A Surprising Heart Remedy
As children, many of us were told to take our vitamins to grow up healthy and strong. Now, scientists in Japan suggest that one particular supplement might do much more—it could help heal a damaged heart.
A study featured in the European Heart Journal by researchers at Osaka University has found that a specific dietary supplement may significantly reverse signs of heart disease in certain patients.
Coronary artery disease (CAD) is a condition where the arteries supplying blood to the heart become narrowed or blocked, often leading to heart attacks. Although treatments like cholesterol-lowering medications and drug-eluting stents (a newer type of stent that delivers medication directly to the artery walls) are widely used, many patients continue to experience poor outcomes. Some individuals do not respond to these conventional therapies at all.
TGCV is an emerging cardiovascular disorder characterized by diffuse narrowing coronary atherosclerosis with triglyceride (TG) deposition caused by defective intracellular lipolysis. TGCV is an often-undiagnosed condition in patients who are resistant to standard therapies.
Panels A and B concern two patients in their 60s with refractory angina pectoris and diabetes mellitus. After being diagnosed with TGCV, they started dietary intake of tricaprin. Their symptoms improved within a couple of months.
Follow-up coronary computed tomography angiography showed marked regression of atherosclerotic lesions with luminal dilatation
(left coronary artery shown as red line in upper panel A; right and left coronary arteries in upper panel B).
The low-attenuation area observed from the adventitial side (yellow and orange area, in the middle, panel A) and its volume (yellow bars in the middle, panel B) were reduced, indicating ameliorated lipid involvement. These observations were associated with increased myocardial lipolysis on iodine-123-β-methyl-p-iodophenylpentadecanoic acid scintigraphy (lower panels).
Credit: 2022, Ken-ichi Hirano, Remarkable regression of diffuse coronary atherosclerosis in patients with triglyceride deposit cardiomyovasculopathy., European Heart Journal
Discovery of a Rare and Resistant CAD Subtype
“Almost 15 years ago, we identified a new type of CAD called triglyceride deposit cardiomyovasculopathy (TGCV), in which the coronary arteries are occluded by triglyceride deposits generated by defective intracellular breakdown of triglycerides in vascular smooth muscle cells,” says lead author of the study Ken-ichi Hirano. “This mechanism makes TGCV distinct from classic cholesterol-induced atherosclerosis, and accounts for patients who are resistant to standard remedies for CAD.”
The research team developed diagnostic guidelines for TGCV and discovered that it is especially common in people with diabetes mellitus and those undergoing hemodialysis. While diagnosing TGCV became possible, finding a successful treatment remained out of reach—until now.
Remarkable Recovery Through a Simple Supplement
“Now we report a remarkable regression of diffuse coronary atherosclerosis in two patients with TGCV,” states Ken-ichi Hirano. “Both had suffered from refractory chest pain and diabetes until diagnosis with TGCV, and subsequent dietary intake of tricaprin led to symptom relief.”
Tricaprin is a commercially available food supplement that promotes lipid breakdown by heart muscle cells. In addition to relieving these patients’ troublesome and painful symptoms, tricaprin also resulted in remarkable regression of the triglyceride build-up in the blood vessels of the heart.
The birth of modern Man
https://chuckincardinal.blogspot.com/
No comments:
Post a Comment
Stick to the subject, NO religion, or Party politics